Craft
  • Home
  •  / Coherus BioSciences
Coherus BioSciences

Coherus BioSciences

Phase III Trials Products

1

FY, 2020

Revenue

$326.6 M

FY, 2021

Market Capitalization

$735.6 M

2022-09-20

Coherus BioSciences Summary

Company summary

Overview
Coherus BioSciences is a biopharmaceutical company that focuses on the biosimilar and immuno-oncology market. It markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor. The company also develops toripalimab, an anti-PD-1 antibody for the treatment of melanoma, urothelial cancer, and nasopharyngeal carcinoma; bevacizumab biosimilar; CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; ranibizumab biosimilar; and CHS-131, a once-daily oral drug candidate for non-alcoholic steatohepatitis and other metabolic conditions.
Type
Public
Founded
2010
HQ
Redwood City, CA, US | view all locations
Website
https://www.coherus.com/
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Dennis M. Lanfear

    Dennis M. Lanfear, President, Chief Executive Officer and Chairman

    • Thomas F. Fitzpatrick

      Thomas F. Fitzpatrick, Chief Legal Officer

    • Richard L. Hameister

      Richard L. Hameister, Chief Technical Officer

    • Vincent R. Anicetti

      Vincent R. Anicetti, Chief Operating Officer

    Operating MetricsView all

    Patent Families

    25

    FY, 2020

    Trials Products Approved

    1

    FY, 2020

    Phase II Trials Products

    1

    FY, 2020

    LocationsView all

    2 locations detected

    • Redwood City, CA HQ

      United States

      333 Twin Dolphin Dr #600

    • Camarillo, CA

      United States

      1000 Avenida Acaso

    Coherus BioSciences Financials

    Summary financials

    Cash (Q2, 2022)
    $275.5M

    Footer menu